January 24, 2025 - 23:03

A consortium of banks, spearheaded by Morgan Stanley, is gearing up to sell approximately $3 billion in debt associated with financing Elon Musk's acquisition of X, the social media platform previously known as Twitter. This move comes as the banks look to offload the financial burden linked to the high-profile buyout.
The decision to sell this substantial amount of debt reflects the banks' strategy to manage their balance sheets amid evolving market conditions. The sale of the debt is expected to attract various investors, as the financial landscape remains dynamic and opportunities for profitable investments continue to emerge.
As the social media industry grapples with challenges and transformations, the implications of Musk's takeover of X are under scrutiny. Stakeholders are closely monitoring how this debt sale will impact the platform's future and its financial stability. The banks involved are poised to navigate the complexities of this transaction while aiming to maximize returns on their investments.
May 14, 2026 - 00:55
Aeluma Announces Third Quarter Fiscal 2026 Financial ResultsAeluma, Inc., a company specializing in compound semiconductor technologies, has released its financial results for the third quarter of fiscal year 2026. The report comes alongside several major...
May 13, 2026 - 11:31
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives ContinueHealthcare distributor McKesson reported first-quarter earnings that missed revenue expectations, though the company continued to push ahead with margin-focused initiatives. For the quarter ending...
May 12, 2026 - 23:07
Prudential Financial Declares Quarterly Dividend on Common StockNEWARK, N.J., May 12, 2026 -- Prudential Financial, Inc. has declared a quarterly dividend of $1.40 per share on its common stock. The payment is scheduled for June 11, 2026, and will go to...
May 12, 2026 - 03:06
Cellectis Reports First Quarter 2026 Financial ResultsCellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs. The company is advancing its pivotal...